---

Heart Failure with Preserved Ejection Fraction (HFpEF): Textbook vs. Current Guidelines

Guideline Priority Note: Recommendations from ACC/AHA (2022 Joint Guideline) and ESC (2021 Guidelines + 2023 Focused Update) are given highest weighting in this synthesis. HFSA, NICE, CCS, and other society guidance are acknowledged where they diverge but carry subordinate weight.

---

1. DEFINITION AND EJECTION FRACTION THRESHOLD

Textbooks

• HFpEF is defined by HF symptoms/signs plus LVEF >40–50%, depending on the textbook and era. Many trials and older editions use LVEF ≥40%. (Braunwald's Heart Disease; Harrison's 22E)
• The spectrum is increasingly divided: HFpEF (LVEF ≥50%) and HFmrEF (LVEF 40–49%), with the understanding that many trial datasets overlap. (Braunwald's; Harrison's)
• HFpEF is no longer viewed as purely a "diastolic disorder"—it is a multifactorial systemic illness involving aging, inflammation, multimorbidity, and metabolic dysregulation. (Braunwald's, p.1035)

⭐ ACC/AHA 2022 Guideline (Highest Weight)

• HFpEF = LVEF ≥50% (Table 4, 2022 AHA/ACC/HFSA Guideline for Management of Heart Failure). This is the authoritative modern threshold.
• HFmrEF = LVEF 41–49%

⭐ ESC 2021/2023 Guideline (Highest Weight)

• Aligned: HFpEF = LVEF ≥50%, HFmrEF = 41–49%
• The 2023 Focused Update explicitly extends some HFpEF recommendations down to EF ≥40% for SGLT2 inhibitors.

Comparison: Textbooks lag slightly—older editions accept EF ≥40% as HFpEF. Both ACC/AHA and ESC have standardized ≥50% as the threshold, but pharmacological trials (DELIVER, EMPEROR-Preserved) enrolled EF ≥40%, creating a practical gray zone that all three sources acknowledge.

---

2. PATHOPHYSIOLOGY

Textbooks (Fuster & Hurst's 15th Ed., Braunwald's, Harrison's 22E)

⭐ ACC/AHA & ESC Guidelines

• Both guidelines reinforce the multimorbidity model and frame HFpEF management around targeting underlying phenotypes (obesity, HTN, AF, CKD)
• The ESC 2021 guidelines introduced the HFA-PEFF algorithm for structured diagnosis incorporating phenotyping

Comparison: Textbooks provide richer mechanistic depth (e.g., titin biology, VV coupling mechanics, sarcomere-level differences by phenotype). Guidelines translate this into actionable diagnostic criteria and phenotype-directed therapy.

---

3. DIAGNOSIS

Textbooks

• Requires: (1) clinical HF diagnosis (symptoms + signs) + (2) LVEF ≥50% (or ≥40% in some frameworks)
• Supporting evidence: elevated BNP/NT-proBNP, echocardiographic diastolic dysfunction markers (E/e' ratio, LA enlargement, dilated IVC), elevated PCWP on invasive hemodynamics
• Pitfall: Up to 30–40% of HFpEF patients (especially obese) have BNP below typical thresholds — diagnosis can be missed (Braunwald's, p.2763)
• Two validated scoring tools: H₂FPEF score and HFA-PEFF score (Braunwald's)
• Echo alone unreliable: diastolic dysfunction is necessary but not sufficient; E/e' often indeterminate (8–15 range); exercise hemodynamics (PCWP ≥25 mmHg with PLR or exercise) may be required (Braunwald's)
• Must exclude mimics: obesity, COPD, CKD, pericardial disease, pulmonary arterial hypertension, HCM, infiltrative disease (amyloidosis, hemochromatosis) (Harrison's 22E)

⭐ ACC/AHA 2022

• Affirms LVEF ≥50% threshold; recognizes diagnostic challenge in obese patients
• Recommends exercise stress testing and invasive hemodynamics when diagnosis is uncertain (Class I, C-EO for hemodynamic evaluation)
• Supports H₂FPEF and HFA-PEFF scores as aids

⭐ ESC 2021/2023

• Endorses the 4-step HFA-PEFF diagnostic algorithm: Pre-test assessment → Echocardiography/BNP → Functional testing → Final aetiology
• Recommends exercise testing with echo or invasive hemodynamics when resting criteria are indeterminate (Class IIa)

Comparison: Strong concordance between textbooks and ACC/AHA/ESC on the diagnostic challenge. The HFA-PEFF algorithm is an ESC construct that has been widely adopted in textbooks. ACC/AHA slightly de-emphasizes the formal algorithm but validates the same diagnostic pathway.

---

4. PHARMACOLOGICAL TREATMENT — DETAILED COMPARISON

4a. SGLT2 Inhibitors ⭐ [Major Update]

Textbook vs. Guideline gap: Braunwald's (2022 edition) and Fuster & Hurst's (15th Ed.) acknowledge the EMPEROR-Preserved data but note guidelines were "not yet updated at time of writing." Harrison's 22E (2025) fully incorporates SGLT2i as foundational therapy. Both ACC/AHA and ESC now rate SGLT2i as the strongest pharmacological recommendation for HFpEF — this is the most significant divergence between older textbooks and current guidelines.

---

4b. Diuretics (Loop + Thiazides)

Full concordance across all sources. Diuretics remain the cornerstone of symptom management with no mortality benefit.

---

4c. MRA (Spironolactone / Finerenone) ⭐ [Emerging Update]

Critical gap: Textbooks reflect the spironolactone-TOPCAT era data (IIb). The FINEARTS-HF trial data with finerenone (published 2024, after the 2022 ACC/AHA guideline) represents a post-guideline advance — current ACC/AHA and ESC are anticipated to upgrade MRA class from IIb to IIa in the next update cycle.

---

4d. ARB / ACEI

Concordance: All sources agree — ARBs have limited, inconsistent benefit. ACEi have no clear HFpEF indication. ACC/AHA and ESC provide weak (IIb) endorsement of ARBs.

---

4e. ARNi (Sacubitril/Valsartan)

PARAGLIDE-HF (acute setting, EF >40%) showed NT-proBNP reduction; clinical benefits confined to EF ≤60%. All sources agree ARNi is a second-line, selected-patient option for HFpEF.

---

4f. Beta-Blockers

Concordance: No beta-blocker recommendation for HFpEF as primary therapy across all sources.

---

4g. Blood Pressure Control

Full concordance — aggressive BP control is the strongest preventive/therapeutic intervention.

---

4h. GLP-1 Agonists (Semaglutide) [Post-Guideline Emerging Therapy]

Important gap: Harrison's 22E (2025) is the first major textbook to fully incorporate GLP-1 data. The 2022 ACC/AHA guideline predates this evidence entirely. ESC 2023 update touched on it only indirectly. This is the frontier of HFpEF pharmacotherapy.

---

4i. Nitrates / PDE5 Inhibitors

Concordance: Explicit guideline prohibition (Class III) aligned with textbook evidence.

---

5. NON-PHARMACOLOGICAL MANAGEMENT

---

6. DIAGNOSTIC SCORING TOOLS

---

7. SUMMARY COMPARISON TABLE

---

8. KEY TENSIONS AND CLINICAL IMPLICATIONS

1. SGLT2 inhibitors are now the pharmacological anchor of HFpEF therapy. ESC 2023 rates them Class IIa, A — the strongest evidence class for any drug in HFpEF. ACC/AHA 2022 also IIa. Harrison's 22E fully endorses this. Older textbook editions that describe SGLT2i as "novel" or "emerging" are now outdated.
2. Finerenone (FINEARTS-HF, 2024) may change the MRA story. The nonsteroidal MRA showed benefit even on background SGLT2i — this post-guideline trial [PMID: 38733212] is likely to upgrade MRA from Class IIb to IIa in the next ACC/AHA/ESC update cycle. Current guidelines and all textbooks pre-date this data.
3. GLP-1 agonists in obese HFpEF — STEP-HFpEF and SUMMIT trials have established meaningful QOL and outcome benefits. Harrison's 22E (2025) is the first major textbook to incorporate this. No formal guideline recommendation exists yet; ACC has signaled forthcoming inclusion. This represents the largest pending therapeutic recommendation.
4. Nitrates and PDE5i — ACC/AHA explicitly labels these Class III (harm/no benefit). Not all textbook editions are as strong in this language. Clinicians should follow the guideline prohibition.
5. Diagnostic threshold mismatch — The ≥50% EF cutoff in guidelines vs. ≥40% in many trials creates patient identification challenges in clinical practice. Provocative hemodynamic testing (exercise PCWP ≥25 mmHg) and scoring tools are underutilized, particularly in obese patients where BNP is suppressed.

---

---

What's in each slide

---

Phase 1 — Reading the Skill Instructions

• Use PptxGenJS (a Node.js library) to build the file programmatically
• Coordinate system is in inches on a 10" × 5.625" canvas (16:9)
• How to add shapes, text boxes, bullets, images, shadows, rounded rectangles
• Critical pitfalls: shadow offsets must be non-negative, charSpacing not letterSpacing, margin: 0 needed for precise alignment
• Design philosophy: don't make boring slides — pick a bold palette, use dominance, avoid plain bullets on white

---

Phase 2 — Design Decisions (Before Writing Any Code)

• #0D2B55 (navy) as the dominant background (~65% visual weight)
• #F59E0B (gold) for ACC/AHA/ESC authority markers
• #2196F3 (bright blue) as the primary accent
• #2E7D32 (green) for Class I recommendations
• #00838F (teal) for Class IIa
• #EF6C00 (orange) for Class IIb
• #E53935 (red) for Class III / No Benefit

---

Phase 3 — Architecture of the JavaScript File

Helper Functions (reusable building blocks)

slideBg()     → Fills the entire slide with navy
accentBar()   → Thin colored stripe at the very top of every slide
footerBar()   → Dark blue footer with source citations
sectionTitle()→ Slide title + gold underline bar
card()        → Generic content card (shape + title + bullets)
classTag()    → Rounded pill badge (e.g. "Class IIa · B-R")

Each Slide Block

1. slideBg(s) — paint the background
2. accentBar(s, color) — top stripe in a slide-specific accent color
3. sectionTitle(s, "Title") — heading + gold rule
4. Content (shapes, text, tables, cards) built with exact x/y/w/h coordinates
5. footerBar(s) — source citations at the bottom

---

Phase 4 — Slide-by-Slide Content Logic

---

Phase 5 — The Drug Comparison Table (Slide 9)

1. Defined column widths as an array [2.2, 1.45, 1.45, 2.0, 2.55]
2. Looped over header cells to draw gold-filled header rectangles
3. Defined 10 data rows as a 2D array
4. Looped over rows, calculating y position from startY + rowIndex × 0.47
5. Applied conditional text coloring: parsed each cell string to detect "Class I", "IIa", "IIb", "III", "Not recommended" → applied the corresponding color from the palette
6. Added a left-side color bar per row using the row's own color in a rowColors[] array

---

Phase 6 — Execution

node create_hfpef_ppt.js

---

What PptxGenJS Actually Does Under the Hood

---

Summary